|
FTO expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.55420010194973E-10 |
| Normal-vs-Stage2 |
6.360700E-04 |
| Normal-vs-Stage3 |
2.04281036531029E-14 |
| Normal-vs-Stage4 |
3.56380480681651E-11 |
| Stage1-vs-Stage2 |
6.324500E-02 |
| Stage1-vs-Stage3 |
9.779500E-02 |
| Stage1-vs-Stage4 |
1.930440E-01 |
| Stage2-vs-Stage3 |
9.742300E-03 |
| Stage2-vs-Stage4 |
1.262170E-02 |
| Stage3-vs-Stage4 |
9.833400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.29849472788146E-11 |
| Normal-vs-AfricanAmerican |
1.284230E-02 |
| Normal-vs-Asian |
3.01309999173327E-09 |
| Caucasian-vs-AfricanAmerican |
3.720400E-03 |
| Caucasian-vs-Asian |
7.697200E-01 |
| AfricanAmerican-vs-Asian |
4.743600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.69190020169208E-10 |
| Normal-vs-Female |
5.44699840787644E-11 |
| Male-vs-Female |
4.525600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.0295997387999E-10 |
| Normal-vs-Age(41-60Yrs) |
1.0941025863076E-11 |
| Normal-vs-Age(61-80Yrs) |
4.39030034549148E-10 |
| Normal-vs-Age(81-100Yrs) |
5.211900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.857400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.658800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.783200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.463600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.379400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.313400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.1991000000059E-05 |
| Classical-VS-Follicular |
4.497600E-01 |
| Classical-VS-Other |
5.790200E-01 |
| Classical-VS-Normal |
1.43629996784966E-09 |
| Tall-VS-Follicular |
1.617610E-04 |
| Tall-VS-Other |
2.167200E-01 |
| Tall-VS-Normal |
1.75137682134618E-12 |
| Follicular-VS-Other |
4.742200E-01 |
| Follicular-VS-Normal |
4.51889999864008E-08 |
| Other-VS-Normal |
2.782900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.45625783338255E-13 |
| Normal-vs-N1 |
1.18038911978147E-12 |
| N0-vs-N1 |
1.040150E-02 |
|
|
